Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers

French, M., Center, R. J., Wilson, K. M., Fleyfel, I., Fernandez, S., Schorcht, A., ... Kelleher, A. D. (2013). Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS, 27(4), 519-528. DOI: 10.1097/QAD.0b013e32835cb720

Published in:
AIDS

DOI:
10.1097/QAD.0b013e32835cb720

Document Version
Peer reviewed version

Link to publication in the UWA Research Repository

General rights
Copyright owners retain the copyright for their material stored in the UWA Research Repository. The University grants no end-user rights beyond those which are provided by the Australian Copyright Act 1968. Users may make use of the material in the Repository providing due attribution is given and the use is in accordance with the Copyright Act 1968.

Take down policy
If you believe this document infringes copyright, raise a complaint by contacting repository-lib@uwa.edu.au. The document will be immediately withdrawn from public access while the complaint is being investigated.

Copyright (c) 2000-2014 Ovid Technologies, Inc.

This is a non-final version of an article published in final form in AIDS. The definitive published version (see citation above) is located on the article abstract page of the publisher, Lippincott Williams & Wilkins.

This version was made available in the UWA Research Repository on 26 March 2014 in compliance with the publisher’s policies on archiving in institutional repositories.

Use of the article is subject to copyright law.
Isotype switched IgG antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ HLA-B alleles in HIV controllers

Martyn A French¹,², Rob J Center³, Kim M Wilson⁴, Ibrahim Fleyfel¹, Sonia Fernandez¹, Anna Schorcht³, Ivan Stratov³, Marit Kramski³, Stephen J Kent³, Anthony D Kelleher⁵

1. School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia.
2. Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Australia.
3. Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia.
4. NRL, Melbourne, Australia
5. Immunovirology Laboratory, St. Vincent's Centre for Applied Medical Research, Sydney, Australia

Word count: Abstract – 249, Body of text – 3507 (with headings)

Corresponding author:
Professor Martyn French
School of Pathology and Laboratory Medicine
Level 2, MRF Building
Rear, 50 Murray St
Perth, 6000
Australia
Tel: +61 8 9224 0205; Fax: +61 8 9224 0204
Email: martyn.french@uwa.edu.au
Abstract

Background

Natural control of HIV infection is associated with CD8+ T cell responses to Gag-encoded antigens of the HIV core and carriage of “protective” HLA-B alleles but some HIV controllers do not possess these attributes. As slower HIV disease progression is associated with high levels of antibodies to HIV Gag proteins, we have examined antibodies to HIV proteins in controllers with and without “protective” HLA-B alleles.

Methods

Plasma from 32 HIV controllers and 21 non-controllers was examined for IgG1 and IgG2 antibodies to HIV proteins in virus lysates by western blot assay and to recombinant (r) p55 and gp140 by ELISA. NK cell-activating antibodies and FcγRIIa-binding immune complexes were also assessed.

Results

Plasma levels of IgG1 antibodies to HIV Gag (p18, p24, rp55) and Pol-encoded (p32, p51, p66) proteins were higher in HIV controllers. In contrast, IgG1 antibodies to Env proteins were less discriminatory, with only anti-gp120 levels being higher in controllers. HIV controllers without “protective” HLA-B alleles had higher plasma levels of IgG1 anti-p32 (p=0.04). High-level IgG2 antibodies to any Gag protein were most common in HIV controllers not carrying a “protective” HLA-B allele, particularly HLA-B57 (p=0.016). ADCC antibodies to gp140 Env protein were higher in elite controllers but did not differentiate HIV controllers with or without “protective” HLA-B alleles. IgG1 was increased in FcγRIIa-binding immune complexes from non-controllers.
Conclusion

We hypothesise that isotype-switched (IgG2+) antibodies to HIV Gag proteins and possibly IgG1 anti-p32 may provide alternative or additional immune control mechanisms to HLA-restricted CD8+ T cell responses in HIV controllers.

Key words: HIV, controllers, IgG2 antibodies, ADCC, immune complexes
**Introduction**

Understanding how the immune system of human immunodeficiency virus (HIV) controllers contain the infection may facilitate the development of therapeutic and possibly preventative HIV vaccines. Natural control of HIV infection is associated with CD8+ T cell responses to HIV core antigens encoded by Gag (1,2) and carriage of particular HLA-B alleles, especially HLA-B*57 but also HLA-B*27, -B*14 and -B*52 and possibly others (3,4,5). However, some HIV controllers do not carry these “protective” HLA-B alleles (3,4), suggesting that immune responses other than CD8+ T cell responses contribute to control of HIV infection. Genetic studies implicate NK cells (6) and there is increasing interest in antibody-dependant cell-mediated cytotoxicity (ADCC) (7,8).

Numerous studies have demonstrated that progression of HIV disease is slower in adults and children with higher serum levels and/or avidity of IgG antibodies to HIV Gag proteins (p17, p24, p55) (9-25). Although these antibodies may be markers of CD4+ T cell help (26), they might have a direct role in the control of HIV replication, particularly antibodies of the IgG2 subclass. Ngo-Giang-Huong et al (27) examined the relationship of plasma levels of IgG1 and IgG2 antibodies to HIV proteins with rates of disease progression and plasma HIV RNA levels in 71 HIV patients who were initially classified as long-term non-progressors. Whereas IgG2 antibodies to gp41 (possibly reflecting an IgG2 antibody response to multiple HIV proteins) were associated with slower disease progression, lower plasma HIV RNA levels were associated with IgG2 antibodies to p55 and p24. Also, we have demonstrated that vaccination of HIV patients receiving ART
with a recombinant DNA vaccine encoding a fowlpox virus vector, HIV Gag-Pol and interferon-γ increased IgG antibodies to vaccine antigens, including IgG2 antibodies to p24, which were associated with partial control of HIV replication after ART was ceased. This was particularly so in individuals carrying a genetic polymorphism of Fcγ receptor (R) IIa that confers a higher affinity of IgG2 binding to FcγRIIa (28). However, Banerjee et al demonstrated that plasma levels of IgG2 antibodies to HIV Gag antigens did not differ between HIV controllers and “chronic progressors” though they did show that plasma levels of IgG1 antibodies to HIV gp120 and p24 were higher in HIV controllers (29). A notable difference between these studies was the use of recombinant HIV antigens in enzyme-linked immunosorbent assays (ELISAs) by Banerjee et al and viral lysates in denaturing western blot (WB) assays in the other studies. It is therefore possible that antigen conformation affects the detection of IgG2 antibodies to HIV antigens.

Isotype diversification of IgG antibodies occurs though class switch recombination of immunoglobulin heavy chain genes, with switching to IgG2 occurring downstream of IgG3 and IgG1 (30), and results in broadening of antibody function. IgG2 antibodies facilitate phagocytosis of antigens through covalent dimerisation (31) and preferential binding to FcγRIIa (32, 33), which primarily mediates phagocytosis of antibodies bound to antigens (34). IgG2 antibodies and FcγRIIa play important roles in the phagocytosis of encapsulated bacteria by neutrophils (35) but FcγRIIa is also the most abundant FcγR on plasmacytoid dendritic cells (pDCs) (36,37) suggesting that FcγRIIa, and possibly
IgG2 antibodies, might affect antiviral immune responses mediated by pDCs (38). Furthermore, IgG2 is the predominant IgG subclass in circulating immune complexes of healthy individuals (39), suggesting that IgG2 antibodies influence the phagocytosis of immune complexes. Of note, HIV infection attenuates IgG2 antibody responses (40).

Here, we have assessed IgG1 and IgG2 antibodies to HIV proteins using WB assays and ELISAs as well as examined ADCC activity and FcγRIIa-binding immune complexes in plasma samples from HIV controllers and non-controllers. Comparison of antibody responses was undertaken in HIV controllers who did or did not carry “protective” HLA-B alleles.

**Methods**

**Patients**

Cryopreserved plasma was obtained from 32 HIV controllers who had a plasma HIV RNA level of <2000 copies/mL (of whom 14 [44%] were elite controllers with levels of <50 copies/mL) on at least three occasions over at least 12 months without ART (4) and 21 HIV non-controllers who had a plasma HIV RNA level of >10,000 copies/mL, a CD4+ T cell count of <100/μL and had not received ART. All patients had provided informed consent for the study.
**Western blot assay for IgG1 and IgG2 antibodies to HIV proteins**

IgG1 and IgG2 antibodies to HIV proteins from viral lysates were assayed by WB based on the method described previously (41) using biotinylated mouse anti-human IgG1 (Sigma, #B6775) or IgG2 (Invitrogen, #05-3540) at 1:1000 dilution and alkaline phosphatase-conjugated streptavidin (Invitrogen #SSN1005) at 1:30,000 dilution. Band intensities were scored from 0 to 4.

**ELISA for antibodies to gp140 Env protein**

IgG1 and IgG2 antibodies to gp140 Env protein were assayed by an ELISA (42), adapted to detect IgG subclasses, in a half-log dilution series using gp140 derived from the subtype B R5-tropic HIV-1\textsubscript{AD8} strain and HRP conjugated monoclonal antibodies to human IgG1 or IgG2 (Invitrogen, Camarillo, CA, clones HP6069 and HP6014, respectively). Wells were considered positive when OD was at least 3-fold higher (IgG1) or 2-fold higher (IgG2) than the OD obtained with HIV negative human sera.

**ELISA for antibodies to Gag**

HIV-1\textsubscript{IIIB} p55 Gag (NIH AIDS Research and Reference Reagent Program, catalogue #3276) was supplemented with 1% SDS and incubated at 37°C for 30 min to improve solubility prior to absorbing onto ELISA plates (200 ng/well) in coating buffer (20 mM Tris pH 8.8, 100 mM NaCl) overnight at room temperature. Wells were blocked with 5% skim milk powder in PBS/0.1% Tween 20 for 1 hour followed by addition of plasma
samples diluted 100-fold in blocking buffer. After 4 hours incubation and washing with PBS/0.1% Tween 20, HRP-conjugated antibodies to human IgG1 or IgG2 in blocking buffer were added and incubated for 1 hour. After washing, ELISAs were developed using standard techniques. Background was defined using HIV negative human sera. Samples were considered positive when the OD was at least 2-fold higher than background.

*NK cell-activating antibodies*

Antibody-induced cytokine production in NK cells was assessed as a surrogate of ADCC, as described previously (8,43). Briefly, 150μl of healthy donor whole blood and immunoglobulin purified from 50μl of patient plasma was incubated at 37°C with either overlapping 15mer HIV-1 peptide pools spanning consensus subtype B Gag or Env (NIH AIDS Reagent Repository) or gp140 Env protein (1μg/ml) for 5 hours in the presence of Brefeldin A and monensin (10μg/ml, Sigma). Following incubation, CD3-CD2+ CD56+ NK lymphocytes were analyzed for expression of intracellular IFNγ. Fluorescent antibodies used were: CD3 (catalog number 347344, fluorescent label PerCP), CD2 (556611, FITC), CD56 (555516, PE), IFNγ (557995, Alexa700) (all from BD Biosciences). We also studied killing of gp140-pulsed CEM.NKr cells in the rapid fluorescent ADCC (RFADCC) assay as previously described (44).

*Analysis of IgG1+ and IgG2+ FcγRIIa-binding immune complexes*
Plasma was thawed at 37°C and centrifuged (300g, 3 minutes) to remove aggregates. Immune complexes were precipitated from plasma by incubation with 3.5% polyethylene glycol 6000 dissolved 1:40 in 0.1M borate (pH 8.4) at 4°C for 16 hours. Following centrifugation (2,500g, 15 minutes), supernatants (containing uncomplexed antibody) were discarded. Pellets (containing immune complexes) were resuspended in PBS and incubated at 37°C until dissolved. Immune complexes were incubated with 5x10⁵ IIA1.6 cells at 4°C for 20 minutes in duplicate. IIA1.6 is a mouse B lymphoma cell line that has been transfected with human FcγRIIa (donated by Professor Mark Hogarth). IIA1.6 cells were kept on ice at all times to prevent internalization of surface receptors and expression of FcγRIIa was confirmed in each assay using a mouse antibody to FcγRIIa (Mab8.7, donated by Professor Mark Hogarth). Cells incubated with immune complexes were washed twice in PBS (300g, 2 minutes), resuspended and stained with either anti-human IgG1-FITC or anti-human IgG2-FITC (Sigma Life Sciences, clones 8c/6-39 and HP-6014, respectively) diluted 1:1000 with PBS (4°C, 20 minutes). Cells were washed twice in PBS (300g, 2 minutes), resuspended in 1% bovine serum albumin/PBS and acquired on a FACS Canto II flow cytometer. Data were analysed using FlowJo software (TreeStar) and results expressed as mean fluorescence intensity of the cell histogram.

**HLA-B typing**

HLA typing was undertaken by sequenced-based typing using genomic DNA in the Department of Clinical Immunology, Royal Perth Hospital or Red Cross Blood Service,
Sydney. Both laboratories are accredited by the American Society for Histocompatibility and Immunogenetics (ASHI).

**Statistics**

Plasma levels of antibodies and immune complexes and ADCC activity were compared using Mann-Whitney *U* tests. The frequency of high-level antibodies in groups of patients was compared by Chi squared tests.

**RESULTS**

**IgG1 antibodies to HIV Gag and Pol-encoded proteins were higher in HIV controllers**

We examined plasma samples for IgG1 and IgG2 antibodies to HIV Gag (p18, p24), *Pol*-encoded (p32, p51, p66) and Env (gp41, gp120) proteins in virus lysates using WB assays and to recombinant Gag (p55) and Env (gp140) proteins using ELISAs (Figure 1). Plasma levels of IgG1 antibodies to all HIV proteins detected by WB assay were higher in HIV controllers than non-controllers, except for anti-gp41, which were high (WB band score of 3 or 4) in all patients (Figure 1A). Plasma samples were tested for IgG1 anti-rp55 by ELISA at a single dilution on two occasions with very good concordance between assays. Twenty six of 32 (81%) HIV controllers had a positive IgG1 antibody to rp55 compared with 5 of 10 (50%) non-controllers (*p*=0.09) (Figure 1C). The titer of IgG1 antibody to rgp140 was also determined by ELISA and endpoint
titers were not significantly different between HIV controllers and non-controllers (p=0.12) (Figure 1E).

**IgG2 antibodies to HIV Gag proteins were most common in HIV controllers**

By WB assay, IgG2 antibodies to gp120 and Pol-encoded proteins were not detected. IgG2 antibodies to p18, p24 and gp41 produced more intense bands in HIV controllers than non-controllers but, notably, the differences were more marked for anti-p18 and -p24 than for anti-gp41 (Figure 1B). Plasma samples were also tested for IgG2 antibodies to rp55 and rgp140 by ELISA as indicated above for IgG1 antibodies. Four of 32 (12.5%) HIV controllers had a positive IgG2 antibody to rp55 compared with none of 10 non-controllers (p=0.14) (Figure 1D). Of note, only one HIV controller with positive IgG2 antibodies to rp55 had high-level IgG2 antibodies to Gag proteins detected by WB assay. The titer of IgG2 antibody to gp140 Env protein did not differ between HIV controllers and non-controllers (p=0.34; Figure 1F).

**NK cell-activating antibodies to HIV gp140 Env protein were higher in HIV controllers**

NK cell-activating antibodies to pools of HIV Env and Gag peptides and to gp140 Env protein were assessed by flow cytometry (8, 43). Antibody-dependant NK cell activity against Gag peptides was generally low and activity against Env peptides was not significantly different between HIV controllers and non-controllers (n=14) (Figure 2A). However, activity against gp140 Env protein was marginally higher in HIV controllers than non-controllers (p=0.09) (Figure 2A). We therefore compared elite controllers with
non-controllers and found significantly higher activity against gp140 Env protein in elite controllers (p=0.01, Figure 2B). Activity against gp140 Env protein in the RFADCC assay (44) was not different between controllers and non-controllers (data not shown).

**IgG1 anti-p32 and IgG2 antibodies to HIV Gag proteins differentiated HIV controllers without ‘protective’ HLA-B alleles from those with these alleles**

If antibodies to HIV proteins contribute to control of HIV replication, they are likely to be higher in HIV controllers who do not carry „protective” HLA-B alleles. Twenty of the 32 (62.5%) HIV controllers carried a „protective” HLA-B allele (B*57, B*52, B*27 or B*14+Cw0802) as defined in the International HIV Controllers Study (4). We therefore compared antibodies in HIV controllers who did or did not carry these alleles (Table 1). Plasma levels of IgG1 antibodies to p24, p51, p66, gp41 and gp120, IgG2 antibodies to gp41 and ADCC antibodies to gp140 Env protein did not differ between groups (p≥0.42). We then interrogated the data for IgG1 anti-p18 and -p32 and IgG2 anti-p18 and -p24 (p≤0.16) to determine if there might be an interaction with HLA-B alleles. For this analysis, patients with HLA-B*57 (n=10) or -B*52 (n=2) and HLA-B*27 (without -B*57) (n=9) or B*14+Cw0802 (n=1) were grouped together because the association with HIV control is stronger for the former than latter alleles (4). In addition to the differences demonstrated between HIV controllers and non-controllers (Figure 1), the clearest association of an antibody response with control of HIV infection was for IgG2 anti-p24 in patients who did not carry a “protective” HLA-B allele or who carried HLA-B*27 or B*14+Cw0802 (Figure 3).
To investigate the possible association of IgG2 antibodies to HIV Gag proteins with control of HIV infection further, we compared patients with HLA-B*57 or -B*52, with HLA-B*27 or B*14+Cw0802 or with no “protective” HLA-B alleles for evidence of a high-level IgG2 antibody response to any Gag protein (WB score of 3 or 4 for anti-p18 or anti-p24 and/or positive anti-rp55). Such an antibody response was demonstrated in 2 of 12 patients with HLA-B*57 or -B*52 (16.5%), 4 of 8 patients with HLA-B*27 or B*14+Cw0802 (50%) and 9 of 12 patients without "protective" HLA-B alleles (75%) (p=0.016 overall and 0.004 for trend, by Chi square test).

**IgG1 and IgG2 content of plasma FcγRIIa-binding immune complexes was similar to non-HIV subjects in HIV controllers but not non-controllers**

We also examined the IgG1 and IgG2 content of plasma FcγRIIa-binding immune complexes (IC) in HIV controllers and non-controllers (n=10) (Figure 4A). Consistent with findings for IgM-IgG IC purified from normal human plasma (39), FcγRIIa-binding IC from non-HIV subjects (n=12) contained IgG2 but not IgG1. Similarly, IgG2 was more abundant than IgG1 in FcγRIIa-binding IC from HIV controllers. In contrast, IgG1 was as abundant as IgG2 in FcγRIIa-binding IC from non-controllers. As HIV controllers had more abundant IgG1 in FcγRIIa-binding IC than non-HIV subjects, we compared elite controllers and virological controllers and found that IgG1 was more abundant in the latter group (Figure 4B).
Discussion

We have demonstrated that particular antibody responses to HIV proteins are associated with control of HIV infection and might contribute to immune control by a mechanism that is distinct from CD8$^{+}$ T cell responses restricted by “protective” HLA-B alleles. As well as confirming that IgG2 antibodies to gp41 are associated with control of HIV infection (27), we demonstrated larger amounts of IgG2 antibodies to HIV Gag proteins in HIV controllers than non-controllers. Moreover, a high-level IgG2 antibody response to any Gag protein (p18, p24 or rp55) correlated with control of HIV infection in patients who did not carry HLA-B*57 more strongly than any of the other antibody responses examined. Plasma levels of IgG1 anti-p32 were also higher in HIV controllers who did not carry “protective” HLA-B alleles. In addition, we have confirmed previous reports that IgG1 antibodies dominate the IgG antibody response to all HIV proteins including in HIV controllers (29,45). We interpret these findings as evidence that IgG2 antibodies to HIV Gag proteins may contribute to protective immune responses against HIV in controllers who do not carry HLA-B*57. As HLA-B*57 is the strongest correlate of immune control of HIV infection (3,4,5,46) and recognizes more viral epitopes than other HLA-B molecules (46), CD8$^{+}$ T cell responses associated with HLA-B*57 may be sufficient in the absence of other immune responses. The finding that IgG1 anti-p32 were higher in HIV controllers who did not carry “protective” HLA-B alleles was of interest because Pol may be a target of ADCC antibodies (47).

Antibody-dependant NK cell activity against HIV gp140 Env protein was higher in HIV controllers than non-controllers, though differences were not statistically significant. However, in a post hoc analysis we found that activity against HIV envelope protein was
higher in elite controllers, consistent with the findings of Lambotte et al (7). Antibody-dependant NK cell activity against HIV envelope protein, however, did not differentiate HIV controllers with or without “protective” HLA-B alleles.

Production of IgG2 antibodies to HIV Gag proteins in HIV controllers might be unexpected because IgG2 antibodies are thought to react preferentially with carbohydrate antigens (48), including glycosylated regions of HIV gp120 (49). However, IgG2 antibodies are produced against protein antigens of other persistent pathogens, such as *Plasmodium falciparum*, and are associated with protection from infection (50). It is therefore conceivable that IgG antibodies to HIV Gag proteins that have isotype switched to IgG2 are associated with control of HIV infection. Alternatively, these antibodies may be a marker of Th1 responses against Gag proteins in HIV controllers (1,2,27). However, we have demonstrated that IgG2 antibodies to Gag proteins were most frequent in HIV controllers without “protective” HLA-B alleles. Although IgG2 binds less avidly to FcγRIIa than IgG3 or IgG1 (32, 33), this IgG subclass is distinguished from others by an ability to form covalent dimers (31) and resistance to the adverse effects of deglycosylation of the Fc region on binding to FcγRIIa (51). HIV infection is associated with degalactosylation of the Fc region of IgG, particularly IgG1 (52), though it is unknown if this is associated with more extensive deglycosylation that might decrease binding of IgG1 to FcγRIIa (51). We suggest that IgG2 antibodies to HIV Gag proteins may contribute to immune control of HIV infection by broadening and enhancing the function of IgG antibodies.
Forthal et al demonstrated that IgG2 antibodies to gp120, elicited by vaccination with recombinant gp120, inhibited the phagocytosis of opsonised HIV-1 viral like particles (VLPs) by monocytes from healthy individuals and argued that IgG2 antibodies adversely affect antiviral antibody activity (49). Monocytes express both FcγRI (a high affinity FcγR) and FcγRIIa (a low affinity FcγR) (37) and it is possible that IgG2 antibodies, which do not bind to FcγRI, interfere with the binding of IgG1 antibodies to that receptor on monocytes. However, pDCs primarily express FcγRIIa (37) and IgG2 antibodies might therefore have a stimulatory rather than inhibitory role for pDCs. Indeed, activation of pDCs by immune complexes binding to FcγRIIa has been demonstrated for several antigens. For example, studies in patients with systemic lupus erythematosus have shown that pDC activation and production of interferon-alpha (IFN-α) is induced by complexes of DNA and anti-DNA IgG binding to FcγRIIa leading to transportation of the immune complexes to endosomes where CpG DNA binds to TLR9 (36, 53). This results in the production of pro-inflammatory and Th1 cytokines as well as IFN-α. A similar mechanism of phagocytosis via FcγRIIa and intracellular transportation to endosomal TLR7 has also been described for immune complexes of Coxsackievirus RNA and antibody (54).

Antibodies to gp41 or gp120 are major components of plasma immune complexes in HIV patients but these immune complexes are not associated with control of HIV infection (55). Plasma immune complexes in HIV patients also contain HIV p24 and probably HIV RNA (56, 57). We therefore speculate that IgG antibodies to HIV Gag proteins induce the production of immune complexes containing HIV RNA and that
isotype switching to IgG2 antibodies facilitates binding of these complexes to FcγRIIa on cells of the innate immune system, such as pDCs. This would permit HIV RNA to be sensed by TLR7 in pDCs, as has been described for coxsackieviruses (54). Furthermore, antibodies to the HIV core, as opposed to envelope, would not increase antibody-enhanced infection of cells, such as macrophages (58). Our analysis of plasma FcγRIIa-binding immune complexes did not demonstrate higher levels of IgG2⁺ complexes in controllers but did demonstrate more abundant IgG1 in FcγRIIa-binding immune complexes of non-controllers than non-HIV subjects and HIV controllers despite lower IgG1 antibody responses to HIV proteins. The significance of this finding is uncertain but IgG1 in FcγRIIa-binding immune complexes might adversely affect their interaction with antigen presenting cells, as shown for IgG3 in IgG-IgM immune complexes (39).

Vaccination with HIV p24, or components of it, has been associated with an anti-HIV effect in a variety of circumstances but immune correlates of that effect are unclear. In addition to our previous findings (28), there have been two studies of note. Vaccination with a combination of four p24-like peptides (Vacc-4x), using strategies to increase antigen processing by cutaneous Langerhan"s cells, induced weak antibody responses and long-lasting delayed-type hypersensitivity and lymphoproliferative responses to the p24-like peptides but did not arrest disease progression after a median time of 7.3 years (59). Furthermore, vaccination of cats with HIV p24 in Ribi/cytokine adjuvant induced cross-reactive antibodies to feline immunodeficiency virus (FIV) p24 and was associated with 78% protection from experimental infection with FIV (60), though the
immunological correlate of protection from infection in the data presented was unclear. We suggest that future studies of vaccines containing HIV p24 should include an analysis of IgG antibody isotype.

We acknowledge that our study has limitations, including multiple comparisons on a small number of patients and that we have demonstrated associations rather than causation. Nevertheless, our findings are sufficiently robust to support further studies of the role of isotype switching of IgG antibodies to HIV Gag proteins in the control of HIV infection.

In summary, we have shown that isotype-switched (IgG2+) antibodies to HIV Gag proteins are associated with natural control of HIV infection, particularly in patients who do not carry HLA-B*57. We suggest that these antibodies might facilitate the activation of innate immune cells, such as pDCs, via FcγRIIa and, thereby, enhance innate immune responses against HIV and/or adaptive immune responses against Gag antigens.

**Acknowledgements**

This study was supported by NHMRC award 510448. HIV-1IIIb p55 Gag and overlapping peptide reagents were obtained from the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. The contribution of Sinthujan Jegaskanda is gratefully acknowledged.
Role of authors

MF, RC, AK and SK devised the study, wrote the protocol and wrote the manuscript.

RC, KW, IF, SF, AS, IS and MK performed the laboratory assays.

All authors viewed and approved the final version of the manuscript.
References


**Legends to Figures**

**Figure 1.** IgG1 and IgG2 antibodies to HIV proteins from a virus lysate assayed by WB assay (A, B) and to Gag (rp55) (C, D) or gp140 Env protein (E, F) assayed by ELISA in HIV controllers and non-controllers. WB assay band intensities were scored from 0-4. Gag ELISA results are reported as ODs with the dashed line indicating the cut-off for a positive result. Antibodies to gp140 Env protein are reported as endpoint titers.

**Figure 2.** NK cell-activating ADCC activity with gp140 Env protein, Env peptide pool and Gag peptide pool in plasma from HIV controllers and non-controllers (A). As there was a trend towards higher values for gp140 Env protein in HIV controllers, elite controllers were compared separately with non-controllers (B). Values are reported as the percentage of CD56+ lymphocytes expressing IFN-γ after incubation with immunoglobulin samples.

**Figure 3.** Plasma levels of IgG1 anti-p18 (A), IgG1 anti-p32 (B), IgG2 anti-p18 (C) and IgG2 anti-p24 (D) in HIV controllers with HLA-B*57 or -B*52, HLA-B*27 or -B*14+Cw0802 or no „protective“ HLA-B alleles. Patients carrying HLA-B*52 (n=2) were grouped with those carrying HLA-B*57 (n=10) and patients carrying HLA-B*14+Cw0802 (n=1) were grouped with those carrying HLA-B*27 without HLA-B*57 (n=9) because the association with control of HIV infection in the International HIV Controllers study (4) was stronger for HLA-B*57 or -B*52 (odds ratio [OR]>6.3) than for HLA-B*27 or -B*14+Cw0802 (OR=2.58-3.41).
Figure 4. FcγRIla-binding IgG1+ and IgG2+immune complexes in plasma from HIV controllers (C), non-controllers (NC) and non-HIV subjects (non-HIV) (A). As values for IgG1 in HIV controllers were higher than in non-HIV subjects, virological controllers (VC) (HIV RNA <2000 copies/mL) were compared with elite controllers (EC) (HIV RNA <50 copies mL) (B). Plasma levels of immune complexes are reported as the mean fluorescence of intensity (MFI) of IgG1 or IgG2 binding to the IIA1.6 cells.
**Table 1.** Comparison of antibody responses to HIV proteins in HIV controllers who do or do not carry ‘protective’ HLA-B alleles

<table>
<thead>
<tr>
<th>Antibody response*</th>
<th>HIV Controllers without ‘protective’ HLA-B alleles# (median, IQR)</th>
<th>HIV Controllers with ‘protective’ HLA-B alleles (median, IQR)</th>
<th>P value^</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG1 anti-p18</td>
<td>4 (3-4)</td>
<td>3 (2-4)</td>
<td>0.11</td>
</tr>
<tr>
<td>IgG1 anti-p24</td>
<td>4(3-4)</td>
<td>4 (2-4)</td>
<td>0.65</td>
</tr>
<tr>
<td>IgG1 anti-p32</td>
<td>3.5 (2.25-4)</td>
<td>2 (2-3)</td>
<td>0.04</td>
</tr>
<tr>
<td>IgG1 anti-p51</td>
<td>4 (2.25-4)</td>
<td>4 (2.25-4)</td>
<td>0.65</td>
</tr>
<tr>
<td>IgG1 anti-p66</td>
<td>4 (4-4)</td>
<td>4 (3.25-4)</td>
<td>0.42</td>
</tr>
<tr>
<td>IgG1 anti-gp41</td>
<td>4 (4-4)</td>
<td>4 (4-4)</td>
<td>1.0</td>
</tr>
<tr>
<td>IgG1 anti-gp120</td>
<td>3.5 (2-4)</td>
<td>3 (2.25-4)</td>
<td>0.95</td>
</tr>
<tr>
<td>IgG2 anti-p18</td>
<td>1.5 (1-3)</td>
<td>1 (1-2)</td>
<td>0.10</td>
</tr>
<tr>
<td>IgG2 anti-p24</td>
<td>1.5 (0-3.75)</td>
<td>0 (0-2)</td>
<td>0.16</td>
</tr>
<tr>
<td>IgG2 anti-gp41</td>
<td>1 (1-2)</td>
<td>1 (1-2)</td>
<td>0.91</td>
</tr>
<tr>
<td>ADCC antibodies to gp140 Env protein</td>
<td>0.218 (0.024 - 0.412)</td>
<td>0.183 (0.048 - 0.634)</td>
<td>0.51</td>
</tr>
</tbody>
</table>

* All antibody responses are reported as WB assay band scores except for ADCC antibodies to gp140 Env protein, which are reported as IFN-γ activity.

#Protective HLA-B alleles = HLA-B*57, -B*27, -B*1402+Cw0802 or -B*52 (4)

^by Mann-Whitney test
Figure 1
Figure 3

A

B

C

D

Figure 3